Mindtech, Synthetic Data Platform Provider, Announces Strategic Partnership With Appen and Raises $3.7 Million
10.3.2022 14:00:00 CET | Business Wire | Press Release
Mindtech Global, developer of the world’s leading platform for the creation of synthetic training data for AI vision systems, has announced a strategic investment round led by Appen, the global leader in data for the AI Lifecycle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310005300/en/
Mindtech’s Chameleon platform: 3D simulation of a lost child in a busy parking lot, creating synthetic data to train a visual AI system. (Photo: Business Wire)
This new investment round, including participation from Appen and existing Mindtech investors, follows a $3.25 million funding round in July 2021 and will be used to support the company’s rapid growth.
In addition to the investment, Appen and Mindtech have formed a commercial partnership to provide a range of real and synthetic images and associated data and metadata annotation services to the market. Appen’s leadership in labelling real-world data combined with Mindtech’s end-to-end platform for the creation and management of synthetic data will accelerate the development of more accurate AI systems.
Mindtech’s platform, Chameleon, is highly complementary to Appen’s existing data and annotation services. Chameleon’s ‘no-code’ platform is designed for the creation and automated annotation of synthetic data to train human-to-human and human-to-world AI applications. Using Chameleon is more than50 times faster than sourcing and annotating ‘real-world’ data.
Mark Brayan, CEO, Appen said, “Synthetic data is an invaluable resource in the training of AI models and when combined with real-world data can enable outstanding results. We’re excited to partner with Mindtech as their automated end-to-end end synthetic data platform produces the right synthetic data for our customers, faster than competing solutions.”
Steve Harris, CEO at Mindtech said, “We’re excited about this strategic partnership with Appen - it’s goingtoenable more customers to rapidly train their AI systems on scalable synthetic data while complementing Appen’s existing products in real-world data collection, management and annotation. By working in partnership, we’ll further accelerate the development of AI systems that better understand how humans interact with each other and the world around them.”
Editor’s Notes
Mindtech Global www.mindtech.global
Mindtech Global is the developer of the world’s leading end-to-end ‘synthetic’ data creation platform for the training of AI vision systems. The company’s Chameleon platform is a step change in the way AI vision systems are trained, helping computers understand and predict human interactions in applications ranging across retail, smart home, healthcare and smart city.
Mindtech is headquartered in the UK, with operations across the US and Far East and is funded by investors including Mercia, Deeptech Labs, In-Q-Tel and Appen.
Interviews, media images and demos available on request.
About Appen www.appen.com
Appen is the global leader in data for the AI Lifecycle. With over 25 years of experience in data sourcing, data annotation, and model evaluation by humans, we enable organizations to launch the world’s most innovative artificial intelligence systems. Our expertise includes a global crowd of over 1 million skilled contractors who speak over 235 languages, in over 70,000 locations and 170 countries, and the industry’s most advanced AI-assisted data annotation platform. Our products and services give leaders in technology, automotive, financial services, retail, healthcare, and governments the confidence to launch world-class AI products. Founded in 1996, Appen has customers and offices globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005300/en/
Contact information
Cat Lenheim
cat@thoughtldr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release First Quarter 2026 Results on May 5, 202614.4.2026 22:15:00 CEST | Press Release
IFF (NYSE: IFF) today announced that it will release its first quarter 2026 earnings results following the market close on Tuesday, May 5, 2026. The management team will host a live webcast on Wednesday, May 6, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.business
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
AACR 2026: First‑in‑Human STC‑1010 Data Show Favorable Safety and Early Immune Engagement in Metastatic MSS Colorectal Cancer14.4.2026 20:00:00 CEST | Press Release
Brenus Pharma announced that new first‑in‑human data will be presented at the AACR Annual Meeting 2026 (April 17–22, San Diego, California). The company continues to advance its lead candidate, STC-1010, a next generation in vivo allogeneic immunotherapy built on the Stimulated Ghost Cells (SGC) technology. The poster will provide a translational overview demonstrating how STC-1010 is administrated in microsatellite‑stable colorectal cancer (MSS CRC), a setting resistant to standards immunotherapy. Clinical findings from BreAK CRC001 (NCT06934538), Phase I/IIa first‑in‑human evaluation of STC‑1010 in unresectable metastatic MSS CRC, first-line setting (n=6; median follow‑up: 6 months) show : Favorable safety with no dose‑limiting toxicities (DLTs) observed. Promising early efficacy, including 100% disease control rate (DCR) in RECIST. Evidence of immune activation, including delayed‑type hypersensitivity (DTH) responses. Exploratory analyses are ongoing to further characterize tumor–im
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance14.4.2026 19:00:00 CEST | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity. Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal. The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
